Cannabidiol (CBD) for Canine Idiopathic Epilepsy: What the Controlled Trials Show

Bottom line

• In dogs with drug-resistant idiopathic epilepsy, cannabidiol (CBD) added to existing antiseizure drugs has produced a statistically significant reduction in seizure frequency versus placebo in two randomized controlled trials and one open-label cohort, but the proportion of dogs reaching the conventional 50%-responder threshold was not significantly different from placebo in the controlled studies.[1][2][3]
• The effect is best characterized as a modest, adjunctive reduction in seizure burden rather than a stand-alone replacement for established antiseizure drugs.[1][2]
• A consistent, reproducible finding across studies is an increase in serum alkaline phosphatase (ALP) activity, so liver enzyme monitoring is warranted during CBD use, particularly alongside other antiseizure drugs.[1][2][3]
• Cannabidiol is metabolized hepatically and can interact with cytochrome P450 enzymes, so concurrent antiseizure medications and other hepatically cleared drugs deserve attention.[4]
• Evidence quality is still limited (small cohorts, short follow-up, heterogeneous products), and CBD is not an FDA-approved veterinary drug for canine epilepsy; product quality and labeling vary widely.[3][4]

Drug facts

• Class: Phytocannabinoid (non-psychotropic cannabinoid); investigational adjunctive antiseizure agent in dogs.
• Mechanism: Multi-target; the mechanism of its anticonvulsant effect is not fully established. CBD is non-psychotropic and is distinct from tetrahydrocannabinol.[4]
• Route: Oral (CBD-infused oils used in the controlled canine trials); investigational long-acting subcutaneous liposomal formulations have been studied for pain.[1][2]
• Indication: No FDA or EMA approval for epilepsy in dogs. Use is off-label/adjunctive and investigational.
• Approval: No approved veterinary CBD product for canine epilepsy as of this writing. (In human medicine, a purified CBD oral solution is approved for specific epilepsy syndromes; that approval does not extend to veterinary species.)
• Label considerations: No veterinary label; product concentration, purity, and contaminant profiles are not standardized across the market.[4]
• Reported adverse effects in dogs: Increased serum ALP; gastrointestinal signs (decreased appetite, vomiting); ataxia at higher exposures.[1][2][3]

A specific patient on cannabidiol?

Get an instant cited answer — no signup needed for your first question. Voyage Clinical Desk brings species-specific dose math, monitoring plans, and peer-reviewed evidence to the case in front of you.

Try Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=cannabidiol-canine-epilepsy

What the evidence shows

Randomized controlled trials in drug-resistant epilepsy

The first randomized, blinded, placebo-controlled clinical trial of oral CBD as an add-on for canine idiopathic epilepsy enrolled 26 client-owned dogs with intractable disease, randomized to CBD-infused oil or placebo for 12 weeks in addition to existing antiseizure treatment.[1] Dogs in the CBD group had a significant reduction in seizure frequency compared with placebo, with a reported median change of 33%. Importantly, the proportion of dogs classified as responders (at least a 50% decrease in seizure activity) was similar between the CBD and placebo groups, and plasma CBD concentrations correlated with the degree of seizure-frequency reduction. The authors concluded that, given that correlation, additional research was warranted to determine whether a higher exposure would achieve a 50%-responder benefit.[1]

A subsequent double-blinded, placebo-controlled crossover study examined this dose-response question directly in 51 dogs with drug-resistant idiopathic epilepsy, each required to have at least two seizures per month while on at least one antiseizure drug.[2] A lower daily dosage met futility requirements after 12 dogs, and a higher daily dosage was used in the remaining 39 dogs. At the higher dosage, the decrease in total seizure frequency was significant compared with placebo: a 24.1% decrease in seizure days occurred with CBD versus a 5.8% increase with placebo. As in the earlier trial, there was no significant difference in the number of responders between phases. Liver enzyme activity increased at both dosages, and decreased appetite and vomiting were more common during the CBD phase.[2]

Taken together, the two controlled trials point in the same direction: CBD as an adjunct produces a real but modest reduction in overall seizure burden, while the harder endpoint of a 50% responder rate has not been reproducibly separated from placebo. This nuance matters when setting client expectations.

Open-label and pilot cohort data

A prospective pilot study in 13 dogs with refractory epilepsy, all receiving multiple concurrent antiseizure drugs, used a single-arm pretest-posttest design with a deliberate start-low, go-slow titration.[3] The investigators reported a significant overall reduction in seizure frequency, with the median falling from 11 to 5 seizures, and noted that 61.5% of dogs achieved at least a 50% reduction in seizure frequency in this uncontrolled setting. The number of seizure clusters decreased significantly. Most hematologic and renal parameters remained stable, but alkaline phosphatase increased significantly, and owners reported improved quality of life.[3] Because this was an uncontrolled cohort, the higher responder figure cannot be directly compared with the placebo-controlled trials, but the cluster-seizure and quality-of-life signals are consistent with the controlled data and are worth tracking in future studies.

Safety, monitoring, and product quality

Across the canine epilepsy studies, the most consistent laboratory finding is an increase in serum alkaline phosphatase, reported in the foundational trial, the dose-response crossover, and the refractory-epilepsy pilot.[1][2][3] Gastrointestinal signs (decreased appetite, vomiting) and, at higher exposures, ataxia have also been described.[1][2] These findings support baseline and periodic liver enzyme monitoring during CBD use, especially when CBD is layered onto other antiseizure drugs that themselves affect the liver.

A separate consideration is pharmacokinetic interaction. A comparative veterinary review of the endocannabinoid system and phytocannabinoids summarizes the pharmacokinetics, efficacy, and tolerability of cannabis derivatives — predominantly CBD-containing products — across dogs, cats, horses, and other species, and underscores that hepatic metabolism is central to CBD disposition.[4] Because CBD undergoes extensive first-pass hepatic metabolism and can modulate cytochrome P450 activity, concurrent antiseizure drugs and other hepatically cleared medications deserve attention when CBD is added to a regimen.[4] Finally, the lack of a standardized veterinary product means that label claims, actual cannabinoid content, and contaminant profiles vary; this variability is a recognized limitation of the current evidence base.[4]

How this fits clinical practice

For dogs whose seizures remain inadequately controlled despite appropriately dosed conventional antiseizure drugs, the current evidence positions CBD as an investigational adjunct that may modestly reduce seizure burden in some patients, not as a replacement for established therapy. The controlled trials support honest client communication: a measurable reduction in overall seizure frequency is plausible, but a halving of seizures (the 50%-responder benchmark) has not been reproducibly demonstrated against placebo.[1][2] Where a clinician elects a trial of CBD, baseline and periodic liver enzyme monitoring is supported by the reproducible ALP signal, and attention to potential interactions with existing antiseizure drugs is prudent given CBD hepatic metabolism.[2][3][4] Specific products, exposures, and titration schedules should be confirmed against a current formulary and the clinician's own judgment rather than generalized from any single study; this page does not recommend a dose.

References

1. McGrath S, Bartner LR, Rao S, Packer RA, Gustafson DL. 2019. Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy. J Am Vet Med Assoc. https://europepmc.org/abstract/MED/31067185
2. Rozental AJ, Weisbeck BG, Corsato Alvarenga I, et al. 2023. The efficacy and safety of cannabidiol as adjunct treatment for drug-resistant idiopathic epilepsy in 51 dogs: A double-blinded crossover study. J Vet Intern Med. https://europepmc.org/articles/PMC10658598
3. Kimram K, Suwanna N, Tiraphut B, et al. 2025. An Exploratory Study of Cannabidiol as an Adjunctive Treatment for Refractory Epilepsy in Dogs. Animals (Basel). https://europepmc.org/articles/PMC12729276
4. Di Salvo A, Chiaradia E, Sforna M, Della Rocca G. 2024. Endocannabinoid system and phytocannabinoids in the main species of veterinary interest: a comparative review. Vet Res Commun. https://europepmc.org/articles/PMC11442603

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=cannabidiol-canine-epilepsy

Changelog

• 2026-06-20: First published.

Related reads

• Levetiracetam for Canine Idiopathic Epilepsy: Comparative Outcomes, Serum Monitoring, and Intranasal Emergency Use
• Zonisamide for Canine Idiopathic Epilepsy: Efficacy, Tolerability, and Therapeutic Drug Monitoring
• Potassium Bromide (KBroVet) for Canine Idiopathic Epilepsy: FDA Full Approval and Clinical Evidence